HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in ADC Online Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Petrou, Articles by McIntosh, Search for Related Content PubMed PubMed Citation Articles by Petrou, Articles by McIntosh, Topic Collections Editor's choice Relevant Articles

Measuring the benefits of growth hormone therapy in children: a role for preference-based approaches?

¹ Health Economics Research Centre, Department of Public Health, University of Oxford, Oxford, UK
² National Perinatal Epidemiology Unit, Department of Public Health, University of Oxford, Oxford, UK

Correspondence to:
Dr S Petrou, National Perinatal Epidemiology Unit, University of Oxford (Old Road Campus), Old Road, Headington, Oxford OX3 7LF, UK; stavros.petrou@npeu.ox.ac.uk

The first 150 words of the full text of this article appear below.

Recombinant human growth hormone has revolutionised the management of children with growth hormone deficiency, chronic renal insufficiency, Turner syndrome, Prader-Willi syndrome, small-for-gestational-age status, idiopathic short stature and other growth disorders in recent decades. The benefits of administering growth hormone to children have commonly been measured in terms of acceleration in linear growth.¹ Although informative, lines of enquiry that measure the benefits of recombinant human growth hormone in natural or physical units, such as acceleration in linear growth, suffer from a number of limitations. Most notably, they are unable to incorporate the several health changes that can result from growth hormone therapy, including the increased risk of a number of adverse effects¹ such as pigmentation and growth of nevi, gynecomastia, pancreatitis and benign intracranial hypertension, within a single measure. In addition, they overlook the broader effects that the treatment may have on children’s physical, mental and social well-being, as well individual . . . [Full text of this article]

Relevant Articles

Facilitating and understanding the family’s choice of injection device for growth hormone therapy by using conjoint analysis

S F Ahmed, W A Smith, and C Blamires
Arch. Dis. Child. 2008 93: 110-114. [Abstract] [Full Text] [PDF]